Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey L Greene

Showing results (31-40 of 77) with videos related to

Pageof 8
Sort By:
Molecular Cell|May 17, 2005
Structural basis for an unexpected mode of SERM-mediated ER antagonismYa-Ling Wu, Xiaojing Yang, Zhong Ren, et al.
The Journal of Biological Chemistry|May 2, 2006
Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivityRobert W Hsieh, Shyamala S Rajan, Sanjay K Sharma, et al.
Endocrinology|September 26, 2013
Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivoKathleen A O'Leary, Fatou Jallow, Debra E Rugowski, et al.
Breast Cancer Research : BCR|March 10, 2022
Selective pressure of endocrine therapy activates the integrated stress response through NFκB signaling in a subpopulation of ER positive breast cancer cellsSvetlana E Semina, Purab Pal, Nidhi S Kansara, et al.
Organic & Biomolecular Chemistry|May 5, 2018
A "cross-stitched" peptide with improved helicity and proteolytic stabilityThomas E Speltz, Christopher G Mayne, Sean W Fanning, et al.
Journal of Virological Methods|March 1, 2011
Removal of lactate dehydrogenase-elevating virus from human-in-mouse breast tumor xenografts by cell-sortingHuiping Liu, Jessica Bockhorn, Rachel Dalton, et al.
Breast Cancer Research : BCR|June 7, 2024
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancerMuriel Lainé, Marianne E Greene, Justyna D Kurleto, et al.
Molecular Cell|February 18, 2004
Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptorsKendall W Nettles, Jun Sun, James T Radek, et al.
Breast Cancer Research : BCR|May 13, 2021
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancerMuriel Lainé, Sean W Fanning, Ya-Fang Chang, et al.
Journal of the American Chemical Society|September 17, 2019
Versatile Peptide Macrocyclization with Diels-Alder CycloadditionsJeffrey E Montgomery, Justin A Donnelly, Sean W Fanning, et al.
Pageof 8

Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
Molecular Cell|May 17, 2005
Structural basis for an unexpected mode of SERM-mediated ER antagonismYa-Ling Wu, Xiaojing Yang, Zhong Ren, et al.
The Journal of Biological Chemistry|May 2, 2006
Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivityRobert W Hsieh, Shyamala S Rajan, Sanjay K Sharma, et al.
Endocrinology|September 26, 2013
Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivoKathleen A O'Leary, Fatou Jallow, Debra E Rugowski, et al.
Breast Cancer Research : BCR|March 10, 2022
Selective pressure of endocrine therapy activates the integrated stress response through NFκB signaling in a subpopulation of ER positive breast cancer cellsSvetlana E Semina, Purab Pal, Nidhi S Kansara, et al.
Organic & Biomolecular Chemistry|May 5, 2018
A "cross-stitched" peptide with improved helicity and proteolytic stabilityThomas E Speltz, Christopher G Mayne, Sean W Fanning, et al.
Journal of Virological Methods|March 1, 2011
Removal of lactate dehydrogenase-elevating virus from human-in-mouse breast tumor xenografts by cell-sortingHuiping Liu, Jessica Bockhorn, Rachel Dalton, et al.
Breast Cancer Research : BCR|June 7, 2024
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancerMuriel Lainé, Marianne E Greene, Justyna D Kurleto, et al.
Molecular Cell|February 18, 2004
Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptorsKendall W Nettles, Jun Sun, James T Radek, et al.
Breast Cancer Research : BCR|May 13, 2021
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancerMuriel Lainé, Sean W Fanning, Ya-Fang Chang, et al.
Journal of the American Chemical Society|September 17, 2019
Versatile Peptide Macrocyclization with Diels-Alder CycloadditionsJeffrey E Montgomery, Justin A Donnelly, Sean W Fanning, et al.
Pageof 8